PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 35547095-2 2022 Immune checkpoint inhibitors (ICIs) based on programmed death-1/programmed death ligand-1 (PD-1/PD-L1) blockade have made a breakthrough with the approval of PD-1 inhibitor for refractory recurrence and/or metastatic (R/M NPC) and the approval of PD-1 inhibitor in combination with gemcitabine and cisplatin as first line for R/M NPC in 2021 in China. Cisplatin 298-307 programmed cell death 1 Homo sapiens 91-95 35547095-2 2022 Immune checkpoint inhibitors (ICIs) based on programmed death-1/programmed death ligand-1 (PD-1/PD-L1) blockade have made a breakthrough with the approval of PD-1 inhibitor for refractory recurrence and/or metastatic (R/M NPC) and the approval of PD-1 inhibitor in combination with gemcitabine and cisplatin as first line for R/M NPC in 2021 in China. Cisplatin 298-307 programmed cell death 1 Homo sapiens 158-162 35236323-10 2022 The correlation analysis between this signature and immunosuppressive molecules, Immunophenoscore (IPS) and chemotherapeutic efficacy demonstrated that low-risk group had a higher IC50 of cisplatin, mitomycin and doxorubicin and negatively related with CTLA4, HAVCR2, LAG3, PDCD1, TIGIT and ICIs treatment represented by CTLA4-/PD-1-, CTLA4 + /PD-1-, CTLA4-/PD-1 + . Cisplatin 189-198 programmed cell death 1 Homo sapiens 275-280 35236323-10 2022 The correlation analysis between this signature and immunosuppressive molecules, Immunophenoscore (IPS) and chemotherapeutic efficacy demonstrated that low-risk group had a higher IC50 of cisplatin, mitomycin and doxorubicin and negatively related with CTLA4, HAVCR2, LAG3, PDCD1, TIGIT and ICIs treatment represented by CTLA4-/PD-1-, CTLA4 + /PD-1-, CTLA4-/PD-1 + . Cisplatin 189-198 programmed cell death 1 Homo sapiens 329-333 35236323-10 2022 The correlation analysis between this signature and immunosuppressive molecules, Immunophenoscore (IPS) and chemotherapeutic efficacy demonstrated that low-risk group had a higher IC50 of cisplatin, mitomycin and doxorubicin and negatively related with CTLA4, HAVCR2, LAG3, PDCD1, TIGIT and ICIs treatment represented by CTLA4-/PD-1-, CTLA4 + /PD-1-, CTLA4-/PD-1 + . Cisplatin 189-198 programmed cell death 1 Homo sapiens 345-349 35236323-10 2022 The correlation analysis between this signature and immunosuppressive molecules, Immunophenoscore (IPS) and chemotherapeutic efficacy demonstrated that low-risk group had a higher IC50 of cisplatin, mitomycin and doxorubicin and negatively related with CTLA4, HAVCR2, LAG3, PDCD1, TIGIT and ICIs treatment represented by CTLA4-/PD-1-, CTLA4 + /PD-1-, CTLA4-/PD-1 + . Cisplatin 189-198 programmed cell death 1 Homo sapiens 359-363 35261780-6 2022 With the response rate of 81.8%, duration of response of 15.2 months, median progression-free survival of 15.5 months, median overall survival of 21.5 months and manageable toxicity in patients with advanced ESCC, we demonstrated that cisplatin-based chemotherapy plus anti-PD-1 antibody is an effective and safe option. Cisplatin 235-244 programmed cell death 1 Homo sapiens 274-278 35261780-8 2022 These results highlight the effectiveness of cisplatin combining with anti-PD-1 antibody in patients with advanced ESCC, revealed its capability to promote the PD-L1 expression in ESCC cells and act synergistically with anti-PD-1 antibody to restore exhausted immune cells activities, thus providing a theoretical basis for further explorations in the mechanism of the combination treatment of cisplatin-based chemotherapy with immune checkpoint inhibitors in ESCC. Cisplatin 45-54 programmed cell death 1 Homo sapiens 75-79 35261780-8 2022 These results highlight the effectiveness of cisplatin combining with anti-PD-1 antibody in patients with advanced ESCC, revealed its capability to promote the PD-L1 expression in ESCC cells and act synergistically with anti-PD-1 antibody to restore exhausted immune cells activities, thus providing a theoretical basis for further explorations in the mechanism of the combination treatment of cisplatin-based chemotherapy with immune checkpoint inhibitors in ESCC. Cisplatin 45-54 programmed cell death 1 Homo sapiens 225-229 35261780-8 2022 These results highlight the effectiveness of cisplatin combining with anti-PD-1 antibody in patients with advanced ESCC, revealed its capability to promote the PD-L1 expression in ESCC cells and act synergistically with anti-PD-1 antibody to restore exhausted immune cells activities, thus providing a theoretical basis for further explorations in the mechanism of the combination treatment of cisplatin-based chemotherapy with immune checkpoint inhibitors in ESCC. Cisplatin 394-403 programmed cell death 1 Homo sapiens 75-79 35261780-8 2022 These results highlight the effectiveness of cisplatin combining with anti-PD-1 antibody in patients with advanced ESCC, revealed its capability to promote the PD-L1 expression in ESCC cells and act synergistically with anti-PD-1 antibody to restore exhausted immune cells activities, thus providing a theoretical basis for further explorations in the mechanism of the combination treatment of cisplatin-based chemotherapy with immune checkpoint inhibitors in ESCC. Cisplatin 394-403 programmed cell death 1 Homo sapiens 225-229 33581579-0 2021 PD-1/PD-L1 enhanced cisplatin resistance in gastric cancer through PI3K/AKT mediated P-gp expression. Cisplatin 20-29 programmed cell death 1 Homo sapiens 0-4 33581579-12 2021 CONCLUSION: PD-1/PD-L1 enhanced cisplatin resistance in gastric cancer through PI3K/AKT mediated P-gp expression. Cisplatin 32-41 programmed cell death 1 Homo sapiens 12-16 33656040-4 2021 Here, cisplatin (CDDP) loaded poly(l-glutamic acid)-graft-methoxy poly(ethylene glycol) complex nanoparticles (CDDP-NPs) are confirmed to increase CD8+ T cells within non-irradiated tumors and boost the abscopal effect of RT plus anti-PD1, and more strongly than CDDP. Cisplatin 6-15 programmed cell death 1 Homo sapiens 235-238 33656040-4 2021 Here, cisplatin (CDDP) loaded poly(l-glutamic acid)-graft-methoxy poly(ethylene glycol) complex nanoparticles (CDDP-NPs) are confirmed to increase CD8+ T cells within non-irradiated tumors and boost the abscopal effect of RT plus anti-PD1, and more strongly than CDDP. Cisplatin 17-21 programmed cell death 1 Homo sapiens 235-238 33656040-4 2021 Here, cisplatin (CDDP) loaded poly(l-glutamic acid)-graft-methoxy poly(ethylene glycol) complex nanoparticles (CDDP-NPs) are confirmed to increase CD8+ T cells within non-irradiated tumors and boost the abscopal effect of RT plus anti-PD1, and more strongly than CDDP. Cisplatin 111-115 programmed cell death 1 Homo sapiens 235-238 33656040-4 2021 Here, cisplatin (CDDP) loaded poly(l-glutamic acid)-graft-methoxy poly(ethylene glycol) complex nanoparticles (CDDP-NPs) are confirmed to increase CD8+ T cells within non-irradiated tumors and boost the abscopal effect of RT plus anti-PD1, and more strongly than CDDP. Cisplatin 111-115 programmed cell death 1 Homo sapiens 235-238 33355035-1 2021 BACKGROUND: Several immuno-oncology (IO) agents targeting programmed death-1 or programmed death-ligand 1 (PD-1/L1) are approved second-line therapy options for patients with locally advanced or metastatic urothelial carcinoma (la/mUC) previously treated with platinum-based chemotherapy or first-line options in patients ineligible for cisplatin whose tumors express PD-L1 or for any platinum-based chemotherapy regardless of PD-L1 expression levels. Cisplatin 337-346 programmed cell death 1 Homo sapiens 107-111 32935617-0 2021 Sequencing of PD-1/L1 Inhibitors and Carboplatin-Based Chemotherapy for Cisplatin-Ineligible Metastatic Urothelial Carcinoma. Cisplatin 72-81 programmed cell death 1 Homo sapiens 14-18 32935617-7 2021 RESULTS: In this multicenter retrospective study, we identified 146 cisplatin-ineligible patients with mUC treated with first-line (1L) PD-1/L1 inhibitor therapy followed by second-line (2L) carboplatin-containing chemotherapy (Group 1, n=43) or the reverse sequence (Group 2, n=103). Cisplatin 68-77 programmed cell death 1 Homo sapiens 136-143 32935617-12 2021 CONCLUSIONS: In this biomarker-unselected cohort of cisplatin-ineligible patients with mUC, PD-1/L1 inhibitor followed by carboplatin-containing chemotherapy and the reverse sequence had comparable OS. Cisplatin 52-61 programmed cell death 1 Homo sapiens 92-99 33430352-3 2021 Here, we investigated whether chemoradiotherapy (CRT), a combination of cisplatin and irradiation, could improve the efficacy of postirradiation anti-programmed cell death 1 (PD-1) treatment in UC. Cisplatin 72-81 programmed cell death 1 Homo sapiens 175-179 32341383-5 2020 An antitumor effect was observed in animals that received anti-PD-1 treatment, alone or in combination with cisplatin, likely due to a mechanism independent of T lymphocytes. Cisplatin 108-117 programmed cell death 1 Homo sapiens 63-67 31086347-8 2019 Together, the clinical and translational data of this study indicate that short-term doxorubicin and cisplatin may induce a more favorable tumor microenvironment and increase the likelihood of response to PD-1 blockade in TNBC. Cisplatin 101-110 programmed cell death 1 Homo sapiens 205-209 30582240-1 2019 BACKGROUND: To evaluate the expression of programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) by using immunohistochemistry analysis in locoregionally advanced nasopharyngeal carcinoma (NPC) patients receiving cisplatin, fluorouracil, and docetaxel followed by concurrent chemoradiotherapy. Cisplatin 222-231 programmed cell death 1 Homo sapiens 42-60 30940805-5 2019 Crizotinib plus cisplatin leads to an increase in the expression of PD-1 and PD-L1 in tumors, coupled to a strong sensitization of NSCLC to immunotherapy with PD-1 antibodies. Cisplatin 16-25 programmed cell death 1 Homo sapiens 68-72 30940805-5 2019 Crizotinib plus cisplatin leads to an increase in the expression of PD-1 and PD-L1 in tumors, coupled to a strong sensitization of NSCLC to immunotherapy with PD-1 antibodies. Cisplatin 16-25 programmed cell death 1 Homo sapiens 159-163 30126243-4 2018 A DNA fragmentation test in the HL-60 cell line has indicated that Pd1 causes comparable proapoptotic effects with regard to cisplatin but at substantially higher concentrations. Cisplatin 125-134 programmed cell death 1 Homo sapiens 67-70 30126243-7 2018 The test for efficient removal of DNA-adducts by the NER synthesis after modification of pBS plasmids with either cisplatin or Pd1 has manifested that the lesions induced by cisplatin are far better recognized and repaired compared those of Pd1. Cisplatin 114-123 programmed cell death 1 Homo sapiens 241-244 30126243-7 2018 The test for efficient removal of DNA-adducts by the NER synthesis after modification of pBS plasmids with either cisplatin or Pd1 has manifested that the lesions induced by cisplatin are far better recognized and repaired compared those of Pd1. Cisplatin 174-183 programmed cell death 1 Homo sapiens 127-130 30126243-7 2018 The test for efficient removal of DNA-adducts by the NER synthesis after modification of pBS plasmids with either cisplatin or Pd1 has manifested that the lesions induced by cisplatin are far better recognized and repaired compared those of Pd1. Cisplatin 174-183 programmed cell death 1 Homo sapiens 241-244 29325739-1 2018 Immunotherapy with programmed cell death 1/ligand 1 (PD-1/PD-L1) checkpoint inhibitors has expanded a previously limited pool of effective treatment options for patients with metastatic urothelial carcinoma, particularly those with recurring or refractory disease and those who are ineligible for cisplatin. Cisplatin 297-306 programmed cell death 1 Homo sapiens 53-57 29325739-8 2018 Anti-PD-1/PD-L1 antibodies have shown favorable clinical activity and tolerability in patients with metastatic urothelial carcinoma refractory to platinum-based therapy or who are ineligible for cisplatin. Cisplatin 195-204 programmed cell death 1 Homo sapiens 5-9 29325739-9 2018 The activity of PD-1/PD-L1 inhibitors is now also being studied as first-line monotherapy in cisplatin-eligible patients in combination with chemotherapy as maintenance therapy after first-line chemotherapy, and in earlier disease states, such as muscle-invasive and non-muscle-invasive bladder cancer. Cisplatin 93-102 programmed cell death 1 Homo sapiens 16-20 28994323-3 2017 Atezolizumab is an engineered humanized anti-PD-L1 monoclonal antibody that inhibits PD-L1 binding to PD-1 and B7.1, enhancing immune-mediated tumor killing and is currently approved as second-line treatment after failure of platinum-based chemotherapy as well as first-line in cisplatin-ineligible patients. Cisplatin 278-287 programmed cell death 1 Homo sapiens 102-115 28801607-5 2017 In contrast, we observed that the expression of PD-1 in NK cells was induced after co-culture with cisplatin-resistant cells. Cisplatin 99-108 programmed cell death 1 Homo sapiens 48-52 28801607-6 2017 We also observed increased susceptibility of cisplatin-resistant cells to NK cell cytotoxicity when neutralizing antibody of PD-1 or PD-L1 was added. Cisplatin 45-54 programmed cell death 1 Homo sapiens 125-129 28819582-7 2017 Thus, it is very likely that cisplatin resistance will lead to high expression of PD-L1/PD-1 which makes them vulnerable to anti PD-1 or anti PD-L1 antibody treatment. Cisplatin 29-38 programmed cell death 1 Homo sapiens 88-92 28819582-7 2017 Thus, it is very likely that cisplatin resistance will lead to high expression of PD-L1/PD-1 which makes them vulnerable to anti PD-1 or anti PD-L1 antibody treatment. Cisplatin 29-38 programmed cell death 1 Homo sapiens 129-133 28730785-0 2017 PDCD1 strengthens the sensitivity of ovarian cancer to cisplatin chemotherapy by promoting apoptosis. Cisplatin 55-64 programmed cell death 1 Homo sapiens 0-5 28730785-8 2017 The CAOV3 and OVCAR3 cells with high expression of PDCD1 were more sensitive to cisplatin. Cisplatin 80-89 programmed cell death 1 Homo sapiens 51-56 28730785-9 2017 The SKOV3 and 3AO cells with low expression of PDCD1 were less sensitive to cisplatin. Cisplatin 76-85 programmed cell death 1 Homo sapiens 47-52 28730785-15 2017 PDCD1 strengthens the sensitivity of ovarian cancer to cisplatin by promoting cisplatin-induced apoptosis. Cisplatin 55-64 programmed cell death 1 Homo sapiens 0-5 28730785-15 2017 PDCD1 strengthens the sensitivity of ovarian cancer to cisplatin by promoting cisplatin-induced apoptosis. Cisplatin 78-87 programmed cell death 1 Homo sapiens 0-5 27610620-0 2016 Elevated Cellular PD1/PD-L1 Expression Confers Acquired Resistance to Cisplatin in Small Cell Lung Cancer Cells. Cisplatin 70-79 programmed cell death 1 Homo sapiens 18-21 27610620-3 2016 Here we report that cell-intrinsic expression of PD1 and PD-L1, two immune checkpoints, is required for sustained expansion of SCLC cells under cisplatin selection. Cisplatin 144-153 programmed cell death 1 Homo sapiens 49-52 27610620-4 2016 Indeed, PD1 and PD-L1 were expressed at a higher level in lung cancer cell lines, tumor tissues, and importantly, in SCLC cells resistant to cisplatin (H69R, H82R), when compared to respective controls. Cisplatin 141-150 programmed cell death 1 Homo sapiens 8-11 27610620-8 2016 Thus, cell intrinsic PD1/PD-L1 signaling may be a predictor for poor efficacy of cisplatin treatment, and targeting the cellular PD1/PD-L1 axis may improve chemosensitization of aggressive SCLC. Cisplatin 81-90 programmed cell death 1 Homo sapiens 21-24